Genetic Clues to Multiple Sclerosis Progression: Linking Risk Variants to Brain Atrophy
The article by Gasperi et al., published in Annals of Neurology in 2023, investigates an important question in multiple sclerosis research: why do some individuals experience more severe long-term disease progression than others? Multiple sclerosis is typically understood as an immune-mediated disorder, but disability progression is increasingly recognized as a process involving neurodegeneration, tissue resilience, and central nervous system vulnerability. The study focuses on the genetic variant rs10191329, located in the DYSF-ZNF638 locus, whose minor allele, rs10191329*A, had previously been associated with worse long-term disability outcomes in a large genome-wide association study.
Rationale for Investigating Brain Atrophy
The authors hypothesized that this genetic risk variant might contribute to disease severity by accelerating brain atrophy, a clinically meaningful marker of neurodegeneration in multiple sclerosis. Brain atrophy reflects the loss of neural tissue over time and has been widely used in imaging studies as an in vivo proxy for disease progression. The key conceptual advance of the article is that it moves beyond genetic association with clinical disability alone and asks whether a specific risk allele can be linked to a measurable biological process visible on magnetic resonance imaging.
Study Design and Patient Cohorts
The study used a two-stage design consisting of a discovery cohort from the Technical University of Munich and a replication cohort from the Karolinska Institute in Stockholm. The discovery cohort included 748 individuals, while the replication cohort included 360 individuals with relapsing multiple sclerosis or clinically isolated syndrome fulfilling MRI dissemination criteria. Participants were required to have paired T1-weighted and FLAIR MRI scans acquired on the same scanner with at least twelve months between scans. This design strengthened the reliability of longitudinal brain-volume measurements and allowed the authors to test whether the genetic association was reproducible across independent populations and scanner protocols.
Imaging and Genetic Methodology
Brain atrophy was quantified as yearly percentage brain volume change, or yPBVC, using the SIENA software tool. Additional MRI outcomes, including white matter lesion volume and volumes of the cerebral cortex, thalamus, putamen, and white matter, were analyzed with SAMSEG. Genotyping was performed using Illumina arrays, followed by standard quality control, phasing, and genotype imputation. Statistical analyses used multivariate linear regression, adjusting for important confounders such as age, sex, ancestry components, MRI scanner, and genotyping array. This methodological framework was appropriate for separating the effect of rs10191329 from demographic, technical, and population-structure influences.
Principal Finding: Increased Brain Atrophy per Risk Allele
The central result was that the rs10191329*A allele was associated with higher rates of brain atrophy in both cohorts. In the discovery cohort, the association estimate was 0.109 with a one-sided p value of 0.001, and in the replication cohort the estimate was 0.115 with a p value of 0.005. In the combined meta-analysis, each additional rs10191329*A allele was associated with approximately 0.11 greater yearly percentage brain volume loss, corresponding to about 27.5% to 28% more brain atrophy relative to the mean yearly brain volume change. The replication of this result across two cohorts and six MRI scanners supports the robustness and potential generalizability of the observation.
Secondary Findings and Biological Interpretation
Exploratory analyses suggested that rs10191329*A was also associated with higher baseline white matter lesion volume and greater yearly atrophy of the thalamus and putamen. However, the authors did not find evidence that the variant was associated with baseline Expanded Disability Status Scale scores or yearly EDSS change in this sample. This distinction is important: the genetic variant showed a clearer relationship with MRI-based neurodegeneration than with short-term clinical disability measures. The authors also compared the variant with longitudinal brain-change data from the ENIGMA consortium and found little evidence that the same variant broadly affects comparable brain-volume metrics in controls, suggesting that its effect may be particularly relevant in the pathological context of multiple sclerosis.
Clinical and Research Implications
This article provides evidence that a genetic variant linked to multiple sclerosis severity is also associated with accelerated brain atrophy, supporting the idea that disease progression may depend partly on inherited differences in central nervous system vulnerability or resilience. The findings may have practical implications for clinical trials, especially those using brain atrophy as an outcome measure, because stratifying participants by rs10191329 genotype could reduce biological heterogeneity. Nevertheless, the study demonstrates association rather than causation, and the molecular mechanism remains unresolved. Future research should determine how this noncoding variant influences neural tissue damage, whether it affects specific cellular pathways, and whether it can help identify new therapeutic targets for preventing progression in multiple sclerosis.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Gasperi, C., Wiltgen, T., McGinnis, J., Cerri, S., Moridi, T., Ouellette, R., ... & Mühlau, M. (2023). A genetic risk variant for multiple sclerosis severity is associated with brain atrophy. Annals of neurology, 94(6), 1080-1085.
